Gabriella D orazi

List of Publications by Year in Descending Order

102 papers	8,694 citations	37 h-index	92 g-index
115 ext. papers	10,522 ext. citations	7.6 avg, IF	5.53 L-index

#	Paper	IF	Citations
102	Zinc Supplementation Enhances the Pro-Death Function of UPR in Lymphoma Cells Exposed to Radiation.. *Biology*, **2022**, 11,	4.9	2
101	VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	2
100	Interconnected Adaptive Responses: A Way Out for Cancer Cells to Avoid Cellular Demise. *Cancers*, **2022**, 14, 2780	6.6	1
99	Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53. *Experimental Cell Research*, **2021**, 408, 112879	4.2	4
98	Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21. *IUBMB Life*, **2021**, 73, 968-977	4.7	3
97	p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53. *Biomolecules*, **2021**, 11,	5.9	2
96	PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function. *Molecular Cancer Therapeutics*, **2021**, 20, 934-945	6.1	5
95	P62/SQSTM1/Keap1/NRF2 Axis Reduces Cancer Cells Death-Sensitivity in Response to Zn(II)-Curcumin Complex. *Biomolecules*, **2021**, 11,	5.9	5
94	Role of UPR Sensor Activation in Cell Death-Survival Decision of Colon Cancer Cells Stressed by DPE Treatment. *Biomedicines*, **2021**, 9,	4.8	2
93	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy*, **2021**, 17, 1-382	10.2	440
92	KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression. *British Journal of Cancer*, **2020**, 123, 298-306	8.7	8
91	Interplay between Endoplasmic Reticulum (ER) Stress and Autophagy Induces Mutant p53H273 Degradation. *Biomolecules*, **2020**, 10,	5.9	4
90	A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 122	12.8	7
89	STAT3 and mutp53 Engage a Positive Feedback Loop Involving HSP90 and the Mevalonate Pathway. *Frontiers in Oncology*, **2020**, 10, 1102	5.3	11
88	Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity. *IUBMB Life*, **2020**, 72, 1634-1639	4.7	4
87	PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR. *Biomolecules*, **2020**, 10,	5.9	3
86	HHV-6A infection dysregulates autophagy/UPR interplay increasing beta amyloid production and tau phosphorylation in astrocytoma cells as well as in primary neurons, possible molecular mechanisms linking viral infection to Alzheimer's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165647	6.9	13

85	Quercetin Interrupts the Positive Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS, Preventing EBV-Driven B Cell Immortalization. *Biomolecules*, **2019**, 9,	5.9	14
84	Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells. *Cancers*, **2019**, 11,	6.6	32
83	Autophagy manipulation as a strategy for efficient anticancer therapies: possible consequences. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 262	12.8	36
82	Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression. *Cancers*, **2019**, 11,	6.6	33
81	HIPK2 role in the tumor-host interaction: Impact on fibroblasts transdifferentiation CAF-like. *IUBMB Life*, **2019**, 71, 2055-2061	4.7	12
80	Reduced chemotherapeutic sensitivity in high glucose condition: implication of antioxidant response. *Oncotarget*, **2019**, 10, 4691-4702	3.3	5
79	STAT3 phosphorylation affects p53/p21 axis and KSHV lytic cycle activation. *Virology*, **2019**, 528, 137-143	3.6	11
78	Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1. *Viruses*, **2018**, 11,	6.2	4
77	Carvacrol reduces adipogenic differentiation by modulating autophagy and ChREBP expression. *PLoS ONE*, **2018**, 13, e0206894	3.7	14
76	Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. *Cellular Oncology (Dordrecht)*, **2017**, 40, 167-180	7.2	51
75	Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. *Journal of Nutritional Biochemistry*, **2017**, 41, 124-136	6.3	124
74	Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. *Cellular Signalling*, **2017**, 40, 239-247	4.9	17
73	p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions. *Journal of Experimental and Clinical Cancer Research*, **2017**, 36, 126	12.8	22
72	Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death. *Journal of Experimental and Clinical Cancer Research*, **2017**, 36, 167	12.8	42
71	Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells and in nude mice while counteracts it in immune competent mice. *OncoImmunology*, **2017**, 6, e1356151	7.2	32
70	Oxidant species are involved in T/B-mediated ERK1/2 phosphorylation that activates p53-p21 axis to promote KSHV lytic cycle in PEL cells. *Free Radical Biology and Medicine*, **2017**, 112, 327-335	7.8	15
69	Hyperglycemia triggers HIPK2 protein degradation. *Oncotarget*, **2017**, 8, 1190-1203	3.3	12
68	Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma. *International Journal of Biochemistry and Cell Biology*, **2016**, 79, 393-400	5.6	35

67	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
66	High glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/β-catenin and p38 MAPK. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 805-813	6.9	31
65	Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging*, **2016**, 8, 603-19	5.6	572
64	ZnCl2 sustains the adriamycin-induced cell death inhibited by high glucose. *Cell Death and Disease*, **2016**, 7, e2280	9.8	10
63	Reactivation of mutant p53 by capsaicin, the major constituent of peppers. *Journal of Experimental and Clinical Cancer Research*, **2016**, 35, 136	12.8	41
62	Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis. *Cancer Letters*, **2016**, 376, 303-9	9.9	40
61	The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. *Journal of Experimental and Clinical Cancer Research*, **2015**, 34, 87	12.8	18
60	Zn(II)-curc targets p53 in thyroid cancer cells. *International Journal of Oncology*, **2015**, 47, 1241-8	4.4	20
59	Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications. *Cell Death and Disease*, **2015**, 6, e1621	9.8	27
58	Gentian violet induces wtp53 transactivation in cancer cells. *International Journal of Oncology*, **2014**, 44, 1084-90	4.4	10
57	High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity. *Journal of Experimental and Clinical Cancer Research*, **2014**, 33, 79	12.8	26
56	Degradation of mutant p53H175 protein by Zn(II) through autophagy. *Cell Death and Disease*, **2014**, 5, e1271	9.8	64
55	SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker. *Oncotarget*, **2014**, 5, 1212-25	3.3	57
54	A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. *Journal of Experimental and Clinical Cancer Research*, **2013**, 32, 72	12.8	48
53	Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line. *Journal of Experimental and Clinical Cancer Research*, **2013**, 32, 79	12.8	25
52	Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. *OncoImmunology*, **2013**, 2, e26198	7.2	35
51	HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma. *Cell Death and Disease*, **2013**, 4, e730	9.8	63
50	Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy. *Cell Death and Disease*, **2013**, 4, e639	9.8	33

49	JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. *PLoS ONE*, **2013**, 8, e75965	3.7	39
48	Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. *Journal of Experimental and Clinical Cancer Research*, **2012**, 31, 63	12.8	59
47	Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. *PLoS ONE*, **2012**, 7, e48342	3.7	19
46	Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. *International Journal of Cancer*, **2012**, 131, E562-8	7.5	40
45	HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. *Cancer Biology and Therapy*, **2012**, 13, 198-205	4.6	21
44	Azurin modulates the association of Mdm2 with p53: SPR evidence from interaction of the full-length proteins. *Journal of Molecular Recognition*, **2011**, 24, 707-14	2.6	25
43	Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. *Cell Cycle*, **2011**, 10, 1679-89	4.7	91
42	HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. *Aging*, **2011**, 3, 33-43	5.6	42
41	Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. *Oncotarget*, **2011**, 2, 1191-202	3.3	24
40	Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. *Oncogene*, **2010**, 29, 4378-87	9.2	106
39	Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. *PLoS ONE*, **2010**, 5, e10171	3.7	35
38	HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition. *Cell Cycle*, **2010**, 9, 1270-5	4.7	42
37	Interaction of p53 with Mdm2 and azurin as studied by atomic force spectroscopy. *Journal of Molecular Recognition*, **2010**, 23, 343-51	2.6	21
36	Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells. *FEBS Letters*, **2010**, 584, 4253-8	3.8	12
35	Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. *Free Radical Biology and Medicine*, **2010**, 48, 1338-46	7.8	52
34	Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. *PLoS ONE*, **2010**, 5, e15048	3.7	76
33	Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?. *Aging*, **2010**, 2, 545-54	5.6	39
32	Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. *Cancer Research*, **2009**, 69, 5978-86	10.1	38

31	Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. *Experimental Cell Research*, **2009**, 315, 67-75	4.2	47
30	Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2009**, 1793, 368-77	4.9	38
29	Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. *Molecular Cancer*, **2009**, 8, 1	42.1	90
28	HIPK2 modulates p53 activity towards pro-apoptotic transcription. *Molecular Cancer*, **2009**, 8, 85	42.1	59
27	Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. *PLoS ONE*, **2009**, 4, e6819	3.7	41
26	Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. *Gynecologic Oncology*, **2008**, 109, 403-10	4.9	17
25	Regulation of vascular endothelial growth factor expression by homeodomain-interacting protein kinase-2. *Journal of Experimental and Clinical Cancer Research*, **2008**, 27, 22	12.8	21
24	Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. *Cancer Research*, **2008**, 68, 3707-14	10.1	60
23	HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. *Cell Death and Differentiation*, **2007**, 14, 1837-9	12.7	26
22	HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. *Biochemical and Biophysical Research Communications*, **2007**, 361, 249-55	3.4	7
21	Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. *Clinical Cancer Research*, **2006**, 12, 735-41	12.9	43
20	Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. *Cancer Letters*, **2006**, 231, 102-12	9.9	16
19	HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. *FEBS Letters*, **2005**, 579, 5473-80	3.8	27
18	HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. *Oncogene*, **2005**, 24, 5431-42	9.2	59
17	p53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. *Cell Death and Differentiation*, **2004**, 11, 596-607	12.7	36
16	HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. *Oncogene*, **2004**, 23, 5185-92	9.2	56
15	N(6)-Methyldeoxyadenosine, a nucleoside commonly found in prokaryotes, induces C2C12 myogenic differentiation. *Biochemical and Biophysical Research Communications*, **2004**, 314, 476-82	3.4	17
14	Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. *Experimental Cell Research*, **2004**, 293, 311-20	4.2	93

13	Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. *Nature Cell Biology*, **2002**, 4, 11-9	23.4	572
12	Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. *Journal of Gene Medicine*, **2000**, 2, 11-21	3.5	26
11	Activation of p53/p21waf1 pathway is associated with senescence during v-Ha-ras transformation of immortal C2C12 myoblasts. *Anticancer Research*, **2000**, 20, 3497-502	2.3	3
10	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. *Gene Therapy*, **1999**, 6, 1064-72	4	30
9	Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. *British Journal of Cancer*, **1998**, 78, 1541-6	8.7	10
8	The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions. *Experimental Dermatology*, **1997**, 6, 321-7	4	14
7	Follicle-stimulating hormone increases the expression of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 and induces TIMP-1 AP-1 site binding complex(es) in prepubertal rat Sertoli cells. *Endocrinology*, **1994**, 135, 2479-87	4.8	48
6	Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma. *International Journal of Cancer*, **1993**, 53, 988-93	7.5	28
5	Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. *Journal of Cellular Physiology*, **1993**, 156, 235-46	7	256
4	Modulation of laminin synthesis in human neuroblastoma cells during retinoic acid induced differentiation. *Cancer Letters*, **1992**, 64, 31-7	9.9	6
3	Xenotransplantation in immunosuppressed nude mice of human solid tumors and acute leukemias directly from patients or in vitro cell lines. *Research in Clinic and Laboratory*, **1989**, 19, 231-43		14
2	Expression and synthesis of fibronectin and laminin by an intestinal epithelial cell line. *Tissue and Cell*, **1988**, 20, 305-12	2.7	15
1	Ewing's sarcoma lines synthesize laminin and fibronectin. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1987**, 410, 375-81		9